What is Immunome's market cap?

Immunome (IMNM) has a market capitalization of $2.7B and trades on NASDAQ.

What is Immunome's revenue and profitability?

Immunome generated $4.0M in trailing twelve-month revenue with a net loss of $224.6M, representing a net margin of -5593.8%, with free cash flow of -$205.5M. These figures are based on the Q1 2026 filing.

Who are Immunome's competitors?

Immunome's key competitors include Seagen, AstraZeneca, Arcus Biosciences, Inc., and others. These companies compete in similar markets and product categories.

Who does Immunome partner with?

Immunome's notable partners include Ayala Pharmaceuticals.

Where is Immunome headquartered?

Immunome is headquartered in United States of America and employs approximately 62 people. It has been publicly traded since 2020.

Immunome

IMNM

Immunome is a clinical-stage biotechnology company focused on developing first-in-class and best-in-class targeted oncology therapies.

Market cap

$2.74B+251%

Revenue$4.0M-63.3%

Net income-$224.6M-9.5%

Free cash flow-$205.5M-27.4%

EPS (diluted)-$2.38+25.2%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 12, 2026

Revenue-Miss by $222.2K EPS-$0.48Beat by $0.12

Read the full report

Next report

Aug 5, 2026 (In 3 weeks)

Revenue estimate$166.7K

EPS estimate-$0.51

Financials

Q1 2026

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation & ratios

Valuation

See full

Market cap$2.74B+251%

Enterprise value$2.16B+250%

P/S681.8×+622×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Competitors

By market cap

Pfizer$138.21B-3.7%

Summit Therapeutics$12.0B-28.4%

ImmunityBio, Inc.$9.3B+287%

Arcus Biosciences$3.8B+333%

Immunome$2.7B+262%

CytomX Therapeutics$861.0M+131%

Greenwich LifeSciences$287.3M+113%

Cardiff Oncology$90.2M-62.8%

By revenue growth

ImmunityBio, Inc.+352%

Arcus Biosciences+67.4%

Pfizer+1.4%

Immunome-63.3%

CytomX Therapeutics-75.9%

By net margin

Pfizer15.65%+6.3pp

Arcus Biosciences-156.36%+121pp

CytomX Therapeutics-166.4%-195pp

ImmunityBio, Inc.-606.15%+704pp

Immunome-5,593.85%-3,719pp

Summit Therapeutics-271,685.0%—

Profile

Immunome is a clinical-stage biotechnology company focused on developing first-in-class and best-in-class targeted oncology therapies. The company leverages deep expertise in antibody-drug conjugates (ADCs) and radioligand therapies to build a pipeline of differentiated assets for the treatment of solid tumors and hematologic malignancies.

Competitive position

Immunome is an emerging player in the ADC space, led by a management team with a track record of commercializing early-generation targeted therapies.

GeographiesGlobal, United States

Customer segmentsOncology patients, Clinical trial participants

Business modelR&D intensive, Biopharmaceutical drug development

SuppliersThird-party diagnostic radiotracer suppliers, Contract manufacturing organizations, Specialized chemical and biological raw material providers

CustomersHospitals, Oncology clinics, Pharmaceutical distributors

CountryUnited States of America

Listed2020

Employees62.0

CEOClay Siegall

SectorHealthcare

IndustryBiotechnology

Websiteimmunome.com

FilingsSEC EDGAR

Ask your AI about Immunome.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's market cap?: Immunome (IMNM) has a market capitalization of $2.7B and trades on NASDAQ.
What is Immunome's revenue and profitability?: Immunome generated $4.0M in trailing twelve-month revenue with a net loss of $224.6M, representing a net margin of -5593.8%, with free cash flow of -$205.5M. These figures are based on the Q1 2026 filing.
Who are Immunome's competitors?: Immunome's key competitors include Seagen, AstraZeneca, Arcus Biosciences, Inc., and others. These companies compete in similar markets and product categories.
Who does Immunome partner with?: Immunome's notable partners include Ayala Pharmaceuticals.
Where is Immunome headquartered?: Immunome is headquartered in United States of America and employs approximately 62 people. It has been publicly traded since 2020.